



## HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

#### Journavx - Non-PDL

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| ,,,,,,,,,   |                             |                                 |
|---|-----------------------------|---------------------------------|
| Member Name:  | Prescriber Name:            |                                 |
| HPP Member Number:  | Fax:                        | Phone:                          |
| Date of Birth:  | Office Contact:             |                                 |
| Member Primary Phone:   | NPI:                        | PA PROMISe ID:                  |
| Address:  | Address:                    |                                 |
| City, State ZIP:  | City, State ZIP:            |                                 |
| ine of Business:   Medicaid  CHIP  Specialty Pharmacy (if applicable):  |                             | olicable):                      |
| Drug Name:  | Strength:                   |                                 |
| Quantity:   | Refills:                    |                                 |
| Directions:   |                             |                                 |
| Diagnosis Code: Diagnosis:  |                             |                                 |
| HPP's maximum approval time is 12 months but may be less depending on the drug.   |                             |                                 |
|   |                             |                                 |
| Disease office have marking at more diseal higher time leading labeled  |                             |                                 |
| Please attach any pertinent medical history including lak   |                             | mber that may support approval. |
| Please answer the fol   | llowing questions and sign. |                                 |
| Q1. The request is for initial treatment with Journavx. If YES, go to 2. If NO, for reauthorization,  |                             |                                 |
| go to 9.  |                             |                                 |
| ☐ Yes   | □ No                        |                                 |
| Q2. The member is 18 years of age or older. If YES, go to 3.  |                             |                                 |
| │<br>│ │ Yes  | □ No                        |                                 |
|   |                             |                                 |
| Q3. The member is prescribed Journavx for an indication of moderate to severe acute pain. If YES, go to 4.  |                             |                                 |
| ☐ Yes   | □ No                        |                                 |
| Q4. Documentation is attached confirming Journavx will not be used to treat chronic pain. If YES, go to 5.  |                             |                                 |
| □Yes  | □No                         |                                 |
| Q5. Documentation is attached showing that the patient has tried and failed at least two of the following medications within the last 30-days: If YES, go to 7. If NO, go to 6. |                             |                                 |
| ☐ a. oral non-steroidal anti-inflammatory drugs (NSAIDs)  |                             |                                 |

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

## HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

#### Journavx - Non-PDL

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| Member Name:  | Prescriber Name: |  |
|---|------------------|--|
| <ul><li>□ b. topical diclofenac sodium gel</li><li>□ c. acetaminophen</li><li>□ d. tramadol</li><li>□ e. opioids</li></ul>  |                  |  |
| Q6. If the patient has not tried and failed at least two alternative drugs: documentation showing the patient has a contraindication or intolerance to all the following:                                 |                  |  |
| <ul><li>□ a. oral non-steroidal anti-inflammatory drugs (NSAIDs)</li><li>□ b. topical diclofenac sodium gel</li><li>□ c. acetaminophen</li></ul>  |                  |  |
| Q7. Documentation is attached showing the dose is not to exceed 150 mg (3 tablets) on day 1, then 100 mg (2 tablets) per day. If YES, go to 8.  |                  |  |
| ☐ Yes   | □ No             |  |
| Q8. Documentation is attached showing the requested treatment duration is for 14 days or less.  |                  |  |
| ☐ Yes   | □ No             |  |
| Q9. For reauthorization: Documentation is attached showing the patient is experiencing a new episode of moderate to severe acute pain, separate and distinct from the previous episode. If YES, go to 10. |                  |  |
| ☐ Yes   | □ No             |  |
| Q10. Documentation is attached showing that the patient has previously had a positive clinical response to therapy.   |                  |  |
| ☐ Yes   | □ No             |  |
| Q11. Documentation is attached showing the dose is not to exceed 150 mg (3 tablets) on day 1, then 100 mg (2 tablets) per day. If YES, go to 12.  |                  |  |
| ☐ Yes   | □No              |  |

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

# HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

### Journavx - Non-PDL

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

| Member Name:  | Prescriber Name: |  |
|---|------------------|--|
| Q12. Documentation is attached showing the requested treatment duration is for 14 days or less. |                  |  |
| ☐ Yes   | □ No             |  |
| Q13. Additional Information:  |                  |  |
|   |                  |  |
| Prescriber Signature  | Date             |  |

v2025